{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:45:34Z","timestamp":1772646334814,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40262-025-01612-2","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T18:05:14Z","timestamp":1768845914000},"page":"431-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Taking Cabozantinib with a Light Breakfast: A Randomized Crossover Pharmacokinetic Study (SKIPPY 1)"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct05263245","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Amy","family":"Rieborn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels A. D.","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia A. C.","family":"Luelmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Kerssemakers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A. P.","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"van der Hulle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"7","key":"1612_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/s1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327. https:\/\/doi.org\/10.1016\/s1470-2045(16)30107-3.","journal-title":"Lancet Oncol"},{"issue":"24","key":"1612_CR2","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/cncr.34493","volume":"128","author":"MS Brose","year":"2022","unstructured":"Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial. Cancer. 2022;128(24):4203\u201312. https:\/\/doi.org\/10.1002\/cncr.34493.","journal-title":"Cancer"},{"key":"1612_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","volume":"94","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115\u201325. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.012.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1612_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2026982.","journal-title":"N Engl J Med"},{"issue":"7","key":"1612_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/cad.0000000000000366","volume":"27","author":"L Nguyen","year":"2016","unstructured":"Nguyen L, Benrimoh N, Xie Y, Offman E, Lacy S. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs. 2016;27(7):669\u201378. https:\/\/doi.org\/10.1097\/cad.0000000000000366.","journal-title":"Anticancer Drugs"},{"key":"1612_CR6","unstructured":"European Medicines Agency. European Public Assessment Report (EPAR) for cabometyx. Updated 5 May 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/cabometyx-epar-public-assessment-report_en.pdf. Accessed 19 Aug 2025."},{"issue":"11","key":"1612_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/jcph.526","volume":"55","author":"L Nguyen","year":"2015","unstructured":"Nguyen L, Holland J, Mamelok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293\u2013302. https:\/\/doi.org\/10.1002\/jcph.526.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1612_CR8","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/jcph.714","volume":"56","author":"L Nguyen","year":"2016","unstructured":"Nguyen L, Holland J, Ramies D, et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 2016;56(9):1130\u201340. https:\/\/doi.org\/10.1002\/jcph.714.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1612_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/jcph.510","volume":"55","author":"L Nguyen","year":"2015","unstructured":"Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012\u201323. https:\/\/doi.org\/10.1002\/jcph.510.","journal-title":"J Clin Pharmacol"},{"key":"1612_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102062","volume":"89","author":"D Castellano","year":"2020","unstructured":"Castellano D, Pablo Maroto J, Benzaghou F, et al. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: implications for patient care. Cancer Treat Rev. 2020;89:102062. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102062.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"1612_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00280-018-3579-7","volume":"81","author":"S Lacy","year":"2018","unstructured":"Lacy S, Nielsen J, Yang B, Miles D, Nguyen L, Hutmacher M. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2018;81(6):1061\u201370. https:\/\/doi.org\/10.1007\/s00280-018-3579-7.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"1612_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","volume":"33","author":"SL Groenland","year":"2022","unstructured":"Groenland SL, van Eerden RAG, Westerdijk K, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann Oncol. 2022;33(10):1071\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2022.06.010.","journal-title":"Ann Oncol"},{"issue":"5","key":"1612_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41416-024-02789-2","volume":"131","author":"MBA van der Kleij","year":"2024","unstructured":"van der Kleij MBA, Guchelaar NAD, Meertens M, et al. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology: an analysis of the closed cohorts of a multicentre prospective study. Br J Cancer. 2024;131(5):843\u201351. https:\/\/doi.org\/10.1038\/s41416-024-02789-2.","journal-title":"Br J Cancer"},{"issue":"1","key":"1612_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12885-022-09338-1","volume":"22","author":"SD Krens","year":"2022","unstructured":"Krens SD, van Erp NP, Groenland SL, et al. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer. 2022;22(1):228. https:\/\/doi.org\/10.1186\/s12885-022-09338-1.","journal-title":"BMC Cancer"},{"issue":"6","key":"1612_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100312","volume":"6","author":"L Cerbone","year":"2021","unstructured":"Cerbone L, Combarel D, Geraud A, et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study. ESMO Open. 2021;6(6):100312. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100312.","journal-title":"ESMO Open"},{"issue":"5","key":"1612_CR16","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/s1470-2045(20)30069-3","volume":"21","author":"GDM Veerman","year":"2020","unstructured":"Veerman GDM, Hussaarts K, Jansman FGA, Koolen SWL, van Leeuwen RWF, Mathijssen RHJ. Clinical implications of food-drug interactions with small-molecule kinase inhibitors. Lancet Oncol. 2020;21(5):e265\u201379. https:\/\/doi.org\/10.1016\/s1470-2045(20)30069-3.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1612_CR17","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40262-024-01379-y","volume":"63","author":"Z Tan","year":"2024","unstructured":"Tan Z, V\u00f6ller S, Yin A, et al. Population pharmacokinetics of cabozantinib in metastatic renal cell carcinoma patients: towards drug expenses saving regimens. Clin Pharmacokinet. 2024;63(6):857\u201369. https:\/\/doi.org\/10.1007\/s40262-024-01379-y.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1612_CR18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/cpt.1515","volume":"106","author":"FJE Lubberman","year":"2019","unstructured":"Lubberman FJE, Gelderblom H, Hamberg P, et al. The effect of using pazopanib with food vs. fasted on pharmacokinetics, patient safety, and preference (DIET study). Clin Pharmacol Ther. 2019;106(5):1076\u201382. https:\/\/doi.org\/10.1002\/cpt.1515.","journal-title":"Clin Pharmacol Ther"},{"key":"1612_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114823","volume":"163","author":"DAC Lanser","year":"2023","unstructured":"Lanser DAC, Van der Kleij MBA, Veerman GDM, et al. Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients. Biomed Pharmacother. 2023;163:114823. https:\/\/doi.org\/10.1016\/j.biopha.2023.114823.","journal-title":"Biomed Pharmacother"},{"key":"1612_CR20","unstructured":"US Food and Drug Administration. Food-effect bioavailability and fed bioequivalence studies: guidance for industry. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/food-effect-bioavailability-and-fed-bioequivalence-studies. Accessed 19 Aug 2025."},{"key":"1612_CR21","unstructured":"US Food and Drug Administration. Clincial pharmacology and biopharmaceutics review(s): 208692Orig1s000\/cabozantinib. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208692Orig1s000ClinPharmR.pdf. Accessed 4 Jan 2026."},{"key":"1612_CR22","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 19 Aug 2025."},{"issue":"5","key":"1612_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","volume":"56","author":"SA Lacy","year":"2017","unstructured":"Lacy SA, Miles DR, Nguyen LT. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet. 2017;56(5):477\u201391. https:\/\/doi.org\/10.1007\/s40262-016-0461-9.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1612_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00003088-199936030-00004","volume":"36","author":"D Fleisher","year":"1999","unstructured":"Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet. 1999;36(3):233\u201354. https:\/\/doi.org\/10.2165\/00003088-199936030-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1612_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00280-011-1688-7","volume":"69","author":"R Abbas","year":"2012","unstructured":"Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69(1):221\u20137. https:\/\/doi.org\/10.1007\/s00280-011-1688-7.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"1612_CR26","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jtho.2017.07.005","volume":"12","author":"BC Cho","year":"2017","unstructured":"Cho BC, Kim DW, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357\u201367. https:\/\/doi.org\/10.1016\/j.jtho.2017.07.005.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1612_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1046\/j.1365-2036.1997.00195.x","volume":"11","author":"U Armbrecht","year":"1997","unstructured":"Armbrecht U, Abucar A, Hameeteman W, Schneider A, Stockbr\u00fcgger RW. Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole: comparison of 24-hour intragastric and oesophageal pH. Aliment Pharmacol Ther. 1997;11(5):959\u201365. https:\/\/doi.org\/10.1046\/j.1365-2036.1997.00195.x.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01612-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:38:15Z","timestamp":1772635095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01612-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01612-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ron Mathijssen received research funding during the previous 3 years from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Deuter Oncology, Echo Pharmaceuticals, Nordic Pharma, Novartis, Pamgene, Pfizer, Roche, Sanofi, and Servier (all paid to the institute, and not related to the current article). In the previous 3 years, Teun van Gelder has received lecture fees and consulting fees from Roche Diagnostics, Thermo Fisher, Chiesi, Otsuka, Veloxis, CSL Behring, and Astellas (all paid to the institute). Teun van Gelder does not have employment or stock ownership at any of these companies, and neither does he have patents or patent applications. Paul Hamberg has received a consultant\u2019s fee from Astellas, MSD, Pfizer AstraZeneca, BMS, and Ipsen. Teun van Gelder and Dirk Jan A.R. Moes are Editorial Board members of\n                      Clinical Pharmacokinetics\n                      . They were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Amy Rieborn, Niels A.D. Guchelaar, Hans Gelderblom, Saskia A.C. Luelmo, Nikki Kerssemakers, Stijn L.W. Koolen, and Tom van der Hulle have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study was approved by the local medical ethics committee (NL80085.058.22, METC Leiden Den Haag Delft), and was registered in ClinicalTrials.gov (NCT05263245) on 11 February, 2022. The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients signed an informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data and trial protocol can be shared upon reasonable request to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The code for analysis of the study data can be shared upon reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AR, NADG, TvG, HG, SACL, NK, APH, SLWK, RHJM, DJARM, and TvdH wrote the manuscript; AR, NADG, RHJM, DJARM, and TvdH designed the research; AR, NADG, RHJM, DJARM, and TvdH performed the research; AR, DJARM, and TvdH analyzed the data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}